DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED
東瑞製葯(控股)有限公司*

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2348)

VOLUNTARY ANNOUNCEMENT

PASSING OF CONSISTENCY EVALUATION FOR

"ENTECAVIR DISPERSIBLE TABLETS 0.5mg" and "AMLODIPINE BESYLATE TABLETS 5mg"

This announcement is made by Dawnrays Pharmaceutical (Holdings) Limited (the "Company") on a voluntary basis to keep shareholders and potential investors informed of the latest development of the Company and its subsidiaries (collectively referred to as the "Group").

The board of directors of the Company (the "Board") is pleased to announce that Suzhou Dawnrays Pharmaceutical Co., Ltd., a subsidiary of the Group, has respectively become the third and fourth domestic drug company that is recognized by National Medical Products Administration for passing the generic drug quality and efficacy consistence evaluation ("Consistence Evaluation") of the 0.5mg Entecavir Dispersible Tablets (brand name "Leiyide") to treat Hepatitis B viruses and 5mg Amlodipine Besylate Tablets (brand name "Anneizhen") to treat high-blood pressure. As part of a significant reform and regulatory initiative introduced by the State Council and National Medical Products Administration in recent years, the Consistence Evaluation fundamentally ensures all generic drugs will truly achieve the same quality standard and efficacy of those drugs originated by international pharmaceutical companies, as a result of which, there is guarantee that the public will enjoy medical treatment and maintain their health.

The Entecavir is an orally administered drug, which is similar to guanine nucleoside, and intended to treat Hepatitis B viruses ("HBV") due to its inhibitive effects on polymerase of HBV. Currently, this drug is mainly used to treat HBVs, which is also used for the initial nucleoside treatment for children who are aged from 2 to less than 18 and suffer from the compensated liver disease due to chronic HBV infection. Given its strong efficacy and effective inhibition of HBVs with a lower drug resistance probability, this drug is the first-line medicine for antiviral treatment for patients with chronic HBVs. Launched to the market in 2010, the Group's product "Leiyide" has been highly recognized among the clinical doctors and patients for its excellent quality, which is also currently the only generic drug of Entecavir with a shelf life of 36 months in the domestic market.

**for identification purpose only*

The Amlodipine Besylate refers to a high-blood pressure drug that contains dihydropyridine calcium antagonists, which is also used to treat chronic stable angina and variant angina. The Group's product "Anneizhen" launched to the market in 2002, current sales volume of the product ranks in front position in the domestic market.

These two products, namely, "Leyide" and "Anneizhen", have passed the Consistence Evaluation. This not only reaffirms the Group's long-term commitment to the "quality first" policy, as well as the quality and efficacy of these two products, but also enables the Group to receive support for bidding for pharmaceutical tenders and medical insurance payment. In addition, alternatives for originator drugs will be expedited so that patients will access more options for good quality drugs at reasonable costs.

By Order of the Board
Dawnrays Pharmaceutical (Holdings) Limited
Li Kei Ling
Chairman

Hong Kong, 27 November 2018

As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; and three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.